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CORRESPONDENCE
Association between rural residency,
group D streptococcal endocarditis and
colon cancer?
10.1111/j.1469-0691.2007.01913.x
We read with interest the article in CMI by
Giannitsioti et al. [1] that analysed the link
between rural residency and a higher proportion
of group D streptococcal infective endocarditis
(GDS IE).
In the last 20 years (1988–2007), we have diag-
nosed 68 cases of GDS IE, with 44 (64.7%) of these
cases occurring in the last 6 years. These cases
comprised 26% of the total number of cases of
infective endocarditis (IE), and were associated
with biotype I and colon tumours in 95% and 57%
of patients, respectively. In total, 56% of the
patients with GDS IE resided in rural areas, as
compared to 35.6% of the 45 patients diagnosed
with IE caused by viridans group streptococci
during the same period (p <0.02). Group D strep-
toccus was the primary cause of IE in our centre,
with a high and increasing incidence. This,
together with a greater frequency in rural areas,
is very similar to the situation reported in France.
However, overall, group D streptococcus consti-
tutes a relatively infrequent cause of IE in Spain,
perhaps because the majority of reports come from
urban areas such as Madrid and Barcelona [2,3].
The association between rural residency and a
higher incidence of GDS IE might be attributed,
at least in part, as suggested by Giannitsioti et al.
[1], to environmental factors, including dietary
habits or contact with animals. Group D strepto-
coccus is an intestinal bacterium that is isolated
frequently from human specimens, as well as
from the faeces of calves, young cattle and dairy
cows [4]. Our region is one of the major areas in
Spain for the production of cattle and dairy
products, and the majority of the population lives
in the countryside in close contact with cattle.
Perhaps the local population has a higher rate of
group D streptococcus faecal carriage, which, in
combination with other factors that have been
insufficiently researched, e.g., a change in the
virulence of certain strains, changes in dietary
habits, and an elderly population with a high
number of degenerative valvulopathies, could
favour this high incidence of IE.
Another question is whether these environ-
mental factors might be associated with a higher
incidence of colon tumours in these patients,
given the association of this cancer with bacter-
aemia caused by Streptococcus bovis biotype I [5].
Accordingly, we analysed 130 cases of bactera-
emia caused by group D streptococcus (with and
without IE) according to biotype and rural resi-
dency. Eighty-nine involved biotype I (53% with
colon cancers), and 41 involved biotype II (7%
with colon cancers, p <0.0001). However, rural
residency was significantly more frequent in
patients with biotype II (80.5% vs. 47%,
p <0.0001). Further epidemiological research is
needed to explain these findings.
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In-vitro activity and in-vivo efficacy of
catheters impregnated with chloroxylenol
and thymol against uropathogens
10.1111/j.1469-0691.2007.01894.x
Further to our recent publication in CMI describ-
ing the antifungal activity of urinary catheters
impregnated with chlorhexidine and chloroxyle-
nol [1], we would like to report some additional
data concerning other antimicrobial options. Uri-
nary tract infection, which is often associated with
an indwelling bladder catheter, accounts for
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c. 40% of all nosocomial infections [2]. The path-
ogenesis of catheter-associated urinary tract infec-
tion generally starts with colonisation of the
surface of an indwelling catheter and the forma-
tion of a biofilm that shelters sessile bacteria from
systemic antibiotics. Most previous approaches
utilising antimicrobial agents have failed to dem-
onstrate significant clinical protection against
infection [3]. In addition, the anti-infective activity
of many currently available antimicrobial-associ-
ated urinary catheters is limited in terms of
durability and spectrum of activity [3,4].
To expand our previous work, 16 French silicone
urinary catheters were impregnated with a solu-
tion of chloroxylenol (CX) 150 mg ⁄mL and thymol
(TH) 400 mg ⁄mL, and then gas-sterilised, as
described previously [1]. CX and TH have been
used clinically for pre-surgery skin preparation
and as an oral antiseptic, respectively [5,6]. The
in-vitro antimicrobial activity of CX ⁄TH-impreg-
nated 2-cm catheter segments was then investi-
gated at baseline, and at 3, 7 and 14 days after
suspension in synthetic urine [7], by determining
the zones of inhibition [8] against ten clinical
isolates (including Gram-positive cocci, Gram-
negative bacilli and Candida) responsible for clin-
ical episodes of infection. The zones of inhibition
observed (Table 1) demonstrated broad-spectrum
activity of the antimicrobial-impregnated catheters
against all ten organisms tested. No zone of
inhibition was observed around control catheter
segments against any of the organisms tested.
The concentrations of CX and TH on impreg-
nated catheter segments were determined using
HPLC. CX and TH were acetone-extracted, in
duplicate, from individual 1-cm catheter seg-
ments, and lyophilised extracts were subse-
quently reconstituted in HPLC buffer consisting
of methanol:water (75:25). Individual samples
were tested in a reversed-phase HPLC system
using a C18 column with a modified flow rate of
2.5 mL ⁄min isocratically as described previously
[9]. HPLC analysis indicated that a 1-cm segment
of antimicrobial-impregnated urinary catheter
contained an average of 1.4 mg of CX and
4.2 mg of TH.
After securing approval from the Institutional
Animal Care and Use Committee, the in-vivo
efficacy of antimicrobial-impregnated catheters
was assessed using a previously described ani-
mal model [1,10]. In total, 32 2-cm catheter
segments were placed in the backs of eight
female New Zealand White specific pathogen-
free rabbits (two antimicrobial-impregnated and
two non-impregnated catheter segments per
rabbit). Each device was inoculated with
105 CFU of Enterobacter cloacae, and the wounds
were then sutured. After 1 week, the rabbits
were humanely killed and the catheter seg-
ments were removed and cultured [11,12].
Device colonisation was defined as growth of
E. cloacae from catheter cultures. The in-vivo
results indicated that only 2 ⁄ 16 (12.5%) antimi-
crobial-impregnated catheters became colonised
with E. cloacae, compared with 10 ⁄ 16 (62.5%) of
the control catheters (p 0.009). Blood cultures
obtained before the animals were killed were
negative for all eight rabbits.
Although some surface-modified urinary cath-
eters described previously have been found to
delay the onset of bacteriuria, none has been
shown in a prospective randomised clinical trial
to have broad-spectrum and durable efficacy in
preventing clinical episodes of catheter-associ-
ated urinary tract infection [4,13]. The present
results indicate that urinary catheters impreg-
nated with CX and TH provide durable broad-
spectrum antimicrobial activity, and previous
studies have indicated that in-vitro zones of
inhibition ‡10–15 mm may predict in-vivo effi-
cacy in animal models [10], which is in agree-
ment with the findings of the present in-vivo
animal study. However, additional studies are
still required to assess the safety and efficacy of
this approach.
ACKNOWLEDGEMENTS
This work was supported, in part, by Ru¨sch Inc.
(Research Triangle Park, NC, USA). The authors
have assigned the rights to patents that describe
Table 1. In-vitro zones of inhibition against uropathogens
(mm)
Organism Baseline 3 days 7 days 14 days
Klebsiella pneumoniae 27 28 25 22
Pseudomonas aeruginosa 14 13 15 9
Escherichia coli 26 22 27 21
Citrobacter diversus 26 26 23 17
Enterobacter cloacae 37 35 32 33
Proteus mirabilis 35 36 30 30
Staphylococcus aureus (MRSA) 39 40 38 42
Enterococcus faecium 48 49 46 36
Enterococcus faecalis 30 27 28 24
Candida albicans 53 46 42 36
MRSA, methicillin-resistant S. aureus.
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